Odyssey Therapeutics Presents New Data on RIPK2 Inhibitor at ACG 2024
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, is set to present promising data on its receptor-interacting protein kinase 2 (RIPK2)...
ABIONYX Presents Positive RACERS Study Results at ASN Kidney Week 2024
ABIONYX Pharma, a company focused on developing innovative therapies using recombinant human apoA-I, announced that its Phase 2b RACERS...
Precision Biosciences Announces First-in-Human Study for Chronic Hepatitis B Treatment
Precision BioSciences, a clinical-stage gene editing company, has announced a significant advancement in its quest to cure chronic hepatitis...
Predicting First-Line Incontinence Treatment Success in Women
Researchers have developed a potential machine learning model that could personalize treatments for female pelvic floor disorders, specifically urinary...
Navigating the Future of Patient Centricity in Clinical Trials
In this interview, we speak with Dr. Stephen Deacon, Chief Scientific Officer at Pharmanovia, about the shift towards decentralized...
Walgreens and AstraZeneca: Pioneering Accessible Clinical Trials
In a groundbreaking collaboration, Walgreens, AstraZeneca, and digital health company Evinova revealed at DPHARM 2024 that they have embarked on a...
Prevnar 20® Recommended for Adults 50+ by ACIP
The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) has recommended expanding the...
Nanoknife® System’s Long-Term Effects Studied in New Trial
AngioDynamics, a medical technology company specializing in vascular health and cancer treatment, has initiated a global registry study to...
OPM-101 RIPK2 Inhibitor Shows Strong Safety, No Cardiac Toxicity in Phase 1 Study
Oncodesign Precision Medicine (OPM) has announced the successful completion of its Phase 1 clinical trial for OPM-101, an orally...
Medable: Top Patient Engagement Trailblazer by Everest Group
Medable, a leading clinical trial technology platform, has been recognized as a Trailblazer in Everest Group’s first-ever “Clinical Trial...